Literature DB >> 19674051

Parkinsonism induced by VNS in a child with double-cortex syndrome.

Arthur Cukiert1, Pedro Paulo Mariani, Jose Augusto Burattini, Cristine Mella Cukiert, Cassio Forster, Carla Baise, Meire Argentoni-Baldochi, Valeria Mello.   

Abstract

We describe a child with epilepsy associated with double-cortex syndrome in whom vagus nerve stimulation (VNS) generated parkinsonian symptoms. A 13-year-old girl presented with refractory secondary generalized epilepsy from the age of 6 years and mental retardation. Her electroencephalography (EEG) showed diffuse polyspike and wave discharges. Magnetic resonance imaging (MRI) showed double-cortex syndrome. She was submitted to extended callosal section at the age of 10 years, which yielded 50% seizure frequency reduction. She was submitted to VNS by the age of 12 years. As stimulation intensity was increased, there was appearance of extrapyramidal symptoms: She developed bilateral tremor and rigidity, and gait and postural disturbance. All symptoms disappeared 7-10 days after VNS was turned off. Several attempts to reactivate VNS led to the same results. During the periods when VNS was on she presented with marked seizure frequency reduction. This is the first report of a clinically evident direct effect of VNS on the basal ganglia.

Entities:  

Mesh:

Year:  2009        PMID: 19674051     DOI: 10.1111/j.1528-1167.2009.02255.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  2 in total

1.  Non-pharmacological treatment options of drug-resistant epilepsy in subcortical band heterotopia: systematic review and illustrative case.

Authors:  Arthur R Kurzbuch; Ben Cooper; Anil Israni; Jonathan R Ellenbogen
Journal:  Childs Nerv Syst       Date:  2022-08-06       Impact factor: 1.532

Review 2.  Late-onset jaw and teeth pain mimicking trigeminal neuralgia associated with chronic vagal nerve stimulation: case series and review of the literature.

Authors:  Gabriela Timarova; Andrej Šteňo
Journal:  BMC Neurol       Date:  2017-06-15       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.